Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

The United Laboratories International Holdings (3933) Stock Price & Analysis

7 Followers

3933 Stock Chart & Stats

HK$7.89-HK$0.02(-0.88%)
At close: 4:00 PM GMT+8
HK$7HK$8HK$9Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 7.85 - HKD 7.98
52-Week Range
HKD 6.67 - HKD 13.72
Previous Close
HKD 7.96
Volume
N/A
Average Volume (3M)
3.93M
Market Cap
HKD 15.54B
Enterprise Value
HKD 10.04B
Total Cash (Recent Filing)
HKD 11.73B
Total Debt (Recent Filing)
HKD 5.95B
Price to Earnings (P/E)
24.1
Beta
1.00
Next Earnings
Mar 30, 2027 (Est.)
EPS Estimate
0.23
Last Dividend Ex-Date
Jul 07, 2026
Dividend Yield
3.79%

Bulls Say, Bears Say

Bulls Say

Conservative Leverage

Moderate leverage and steadily rising equity provide financial resilience and preserve capacity to fund operations or strategic investment. Asset growth also indicates the company has expanded its operating scale without relying on excessive borrowing, supporting stability over the coming quarters.

Healthy Gross Margin

A gross margin near 42% gives the business a meaningful buffer to absorb operating pressures while retaining funds for research, manufacturing, and commercialization. Although profitability has weakened, this underlying margin profile supports continued viability and investment in the pharmaceutical portfolio.

Integrated Business Model

Operating across research, development, manufacturing, APIs, and finished medicines gives the company broad participation across the pharmaceutical value chain. This integrated model can support product control, internal capabilities, and multiple routes to market through prescription and hospital channels.

Bears Say

Revenue Contraction

The shift from earlier expansion to flat revenue and then an approximately 8.7% decline signals weaker commercial momentum. If this persists, slower top-line growth could reduce operating leverage, limit reinvestment capacity, and make recovery in earnings more dependent on cost control.

Margin And Return Pressure

Lower net margins and ROE show that the company is generating less profit from both sales and its equity base. Continued deterioration would weaken earnings quality and capital efficiency, potentially constraining the resources available for product development, expansion, and shareholder returns.

Weak Cash Conversion

Low and volatile free cash flow relative to reported income raises concerns about the durability of earnings as internally generated cash. This can reduce flexibility for investment, debt management, and distributions, especially if weaker cash conversion continues alongside declining profitability.

The United Laboratories International Holdings News

3933 FAQ

What was The United Laboratories International Holdings’s price range in the past 12 months?
The United Laboratories International Holdings lowest stock price was HK$6.67 and its highest was HK$13.72 in the past 12 months.
What is The United Laboratories International Holdings’s market cap?
The United Laboratories International Holdings’s market cap is HK$15.54B.
When is The United Laboratories International Holdings’s upcoming earnings report date?
The United Laboratories International Holdings’s next earnings report is estimated for Mar 30, 2027 (not yet confirmed), which is in 138 days.
How were The United Laboratories International Holdings’s earnings last quarter?
The United Laboratories International Holdings released its earnings results on Aug 31, 2026. The company reported HK$0.207 earnings per share for the quarter, beating the consensus estimate of HK$0.153 by HK$0.054.
Is The United Laboratories International Holdings overvalued?
According to Wall Street analysts The United Laboratories International Holdings’s price is currently Undervalued.
Does The United Laboratories International Holdings pay dividends?
The United Laboratories International Holdings pays an annual dividend of HK$0.299 which represents an annual dividend yield of 3.79%. See more information on The United Laboratories International Holdings dividends here
What is The United Laboratories International Holdings’s EPS estimate?
The United Laboratories International Holdings’s EPS estimate is 0.23.
How many shares outstanding does The United Laboratories International Holdings have?
The United Laboratories International Holdings has 1,970,276,500 shares outstanding.
What happened to The United Laboratories International Holdings’s price movement after its last earnings report?
The United Laboratories International Holdings reported an EPS of HK$0.207 in its last earnings report, beating expectations of HK$0.153. Following the earnings report the stock price went down -3.398%.
Which hedge fund is a major shareholder of The United Laboratories International Holdings?
Currently, no hedge funds are holding shares in HK:3933
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology